ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products - Université de Lille Accéder directement au contenu
Article Dans Une Revue Clinical and experimental rheumatology Année : 2023

ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

1 Azienda Ospedaliero-Universitaria Pisana = Cisanello University Hospital [Pisa]
2 IRCCS Ospedale San Raffaele [Milan, Italy]
3 ULISBOA - Universidade de Lisboa = University of Lisbon = Université de Lisbonne
4 UNISA - Università degli Studi di Salerno = University of Salerno
5 Università degli Studi di Roma Tor Vergata [Roma, Italia] = University of Rome Tor Vergata [Rome, Italy] = Université de Rome Tor Vergata [Rome, Italie]
6 UMCL - University Medical Centre Ljubljana [Ljubljana, Slovenia]
7 Hôpital Raymond Poincaré (Garches) [GHU AP-HP Université Paris-Saclay]
8 UOC - University of Crete [Heraklion]
9 UniFE - Università degli Studi di Ferrara = University of Ferrara
10 RSU - Riga Stradins University
11 HU Berlin - Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin
12 Ghent University Hospital
13 Hospital Universitario 12 de Octubre [Madrid]
14 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
15 IRCCS AOU San Martino - Istituto di ricovero e cura a carattere scientifico Azienda Ospedaliera Universitaria "San Martino"
16 Technical University of Cluj-Napoca
17 Ospedale San Raffaele
18 Universidade do Porto = University of Porto
19 LIRIC - Lille Inflammation Research International Center - U 995
20 AOUP - Azienda Ospedale Università di Padova = Hospital-University of Padua
21 Rigshospitalet [Copenhagen]
22 Universiteit Utrecht / Utrecht University [Utrecht]
23 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
24 UNIVPM - Polytechnic University of Marche [Ancona, Italy] / Università Politecnica delle Marche [Ancona, Italia]
25 Semmelweis University of Medicine [Budapest]
26 Warsaw University of Technology [Warsaw]
27 KTU - Kaunas University of Technology
28 University of Pisa - Università di Pisa
29 UBB - Babes-Bolyai University [Cluj-Napoca]
30 CHU de Bordeaux Pellegrin [Bordeaux]
31 University Hospital Düsseldorf
32 UNIMIB - Università degli Studi di Milano-Bicocca = University of Milano-Bicocca
33 UniFI - Università degli Studi di Firenze = University of Florence = Université de Florence
34 UvA - University of Amsterdam [Amsterdam] = Universiteit van Amsterdam
35 UniBs - Università degli Studi di Brescia = University of Brescia
36 Radboud University Medical Center [Nijmegen]
37 NKUA - National and Kapodistrian University of Athens
S. Aguilera
  • Fonction : Auteur
J. Andersen
  • Fonction : Auteur
C. Bouillot
I. Galetti
  • Fonction : Auteur
C. Richez

Résumé

Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So far, some autoimmune rheumatic disease (ARD) patients with COVID-19 have been treated with antiviral therapies or anti-SARS-CoV-2 antibody products. However, there is no homogeneous approach to these treatment strategies. This issue was addressed within the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) in a discussion among experts and patient’s representatives in the context of the rare and complex connective tissue diseases (rCTDs) covered by the Network. ERN ReCONNET is one of the 24 ERNs launched by the European Commission in 2017 with the aim of tackling low prevalence and rare diseases that require highly specialised treatment and promoting concentration of knowledge and resources through virtual networks involving healthcare providers (HCPs) across the European Union (EU). Considering the urgent need to provide guidance not only to the rCTDs community, but also to the whole ARDs community, a multidisciplinary Task Force, including expert clinicians and European Patient Advocacy Group (ePAG) Advocates, was created in the framework of ERN ReCONNET with the aim of developing overarching principles (OP) and points-to-consider (PtC) on a homogenous approach to treat immunocompromised patients with ARDs (with a particular focus on CTDs) affected by COVID-19 using antiviral therapies and anti-SARS-CoV-2 antibody products. The present work reports the final OP and PtC agreed by the Task Force.

Dates et versions

hal-04547728 , version 1 (16-04-2024)

Identifiants

Citer

R. Talarico, G. A. Ramirez, S. C. Barreira, C. Cardamone, P. Triggianese, et al.. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products. Clinical and experimental rheumatology, 2023, Clinical and experimental rheumatology, 41, ⟨10.55563/clinexprheumatol/jpargp⟩. ⟨hal-04547728⟩
25 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More